About the Company
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ADMA News
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
ADMA Biologics (NASDAQ:ADMA) has been analyzed by 6 analysts in the last three months, revealing a diverse range of ...
ADMA Biologics Poised for Robust Growth: Buy Rating Affirmed with Enhanced Price Target
ADMA Biologics (ADMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram ...
ADMA Biologics Inc ADMA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
ADMA Biologics, Inc. (ADMA) Q4 2023 Earnings Call Transcript
Good afternoon. And welcome to the ADMA Biologics Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Wednesday, February 28, 2024. At this time, all ...
ADMA Biologics Announces CFO Transition
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company ...
ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA (1) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income ...
ADMA Biologics Inc Reports Robust Revenue Growth and Positive Adjusted Net Income for FY 2023
Revenue Growth: ADMA Biologics Inc (NASDAQ:ADMA) reported a 68% increase in total revenues for FY 2023, reaching $258.2 million. Adjusted EBITDA: The company achieved $40.3 million in adjusted EBITDA ...
Q4 2023 ADMA Biologics Inc Earnings Call
Skyler Bloom; Senior Director, Corporate Strategy & Business Development; ADMA Biologics, Inc. Adam Grossman; Founder, Director, President & CEO; ADMA Biologics, Inc ...
ADMA Biologics Inc
Below is a summary of the major fundamental and technical factors we consider when determining our overall recommendation of ADMA shares. It is provided in order to give you a deeper understanding ...
ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call Transcript February 28, 2024 ADMA Biologics, Inc. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $0.02.
ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call Transcript
ADMA Biologics, Inc. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $0.02. ADMA isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call Transcript
It can only improve, Gary, and I don’t want to say, I want to stop making BIVIGAM, but look, ADMA Biologics founding principles were to make the products that nobody else wants to make.
Loading the latest forecasts...